https://www.selleckchem.com/pr....oducts/amenamevir.ht
3 (IQR 1.8-13.1) years. Using GSRS, 88% of participants reported at least 1 gastrointestinal symptom, most commonly indigestion (57%) and diarrhea (54%). Using GIQLI, 42% and 38% of participants reported mild and moderate QOL impairment, respectively. Gastrointestinal symptoms were predicted by female sex (coefficient-0.11, 95% CI-0.21 to-0.02) and mycophenolate (coefficient 0.0001, 95% CI 0.0001 to 0.0002), and were associated with poorer QOL (coefficient-0.38, 95% CI-0.45 to-0.3. Similar findings were observed using SAGIS for gas
Like
Comment
Share
